Physician profile
Rina Patel
NPI 1033664552
$7,346.87
in general payments reported to CMS, 2019-2025
33 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $106 · 2023: $1,335 · 2024: $3,101 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,749.93 |
| Education | $128.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.36 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $821.98 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $676.51 | 2023-2025 | |
| Janssen Biotech, INC. | $559.73 | 2023-2025 | Stelara, Tremfya, Remicade |
| E.R. Squibb & Sons, L.L.C. | $455.07 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $439.07 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $308.69 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $256.86 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $202.13 | 2023-2025 | Eohilia, Gattex, Entyvio |
| Pfizer INC. | $178.89 | 2023-2025 | |
| Evoke Pharma, INC. | $177.38 | 2023-2024 | Gimoti |
| Aimmune Therapeutics, INC. | $164.95 | 2024-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $158.70 | 2024-2025 | Voquezna |
| Celgene Corporation | $140.99 | 2021-2023 | Zeposia |
| Celltrion USA INC. | $138.27 | 2025 | Vegzelma |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $137.72 | 2024 | Stelara |
| Novo Nordisk INC | $135.99 | 2025 | Wegovy |
| Ardelyx, INC. | $129.35 | 2024-2025 | Ibsrela |
| Coherus Oncology, INC. | $124.99 | 2021 | |
| Braintree Laboratories, INC. | $124.40 | 2023-2025 | Suflave, Sutab |
| Ars Pharmaceuticals Operations, INC. | $124.06 | 2025 | Neffy |
| Ferring Pharmaceuticals INC. | $98.75 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $95.71 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $90.38 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $81.40 | 2023-2024 | Dificid, Zerbaxa |
| Madrigal Pharmaceuticals | $62.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $46.24 | 2023 | Talicia |
| Biocon Biologics INC | $43.81 | 2025 | Yesintek |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Sandoz INC. | $34.52 | 2023-2024 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $28.69 | 2023-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $17.81 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.51 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.